Phathom Pharmaceuticals, Inc.
PHAT
$11.04
$0.666.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,049.81% | 3,055.71% | 8,001.47% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,049.81% | 3,055.71% | 8,001.47% | -- | -- |
| Cost of Revenue | 658.41% | 1,800.67% | 4,674.25% | -- | -- |
| Gross Profit | 1,146.76% | 3,427.64% | 9,080.39% | -- | -- |
| SG&A Expenses | 52.36% | 100.28% | 146.48% | 195.74% | 137.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.80% | 75.53% | 98.05% | 118.07% | 74.04% |
| Operating Income | -6.41% | -38.22% | -65.84% | -99.84% | -67.47% |
| Income Before Tax | -11.12% | -40.21% | -65.84% | -91.70% | -60.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.12% | -40.21% | -65.84% | -91.70% | -60.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.12% | -40.21% | -65.84% | -91.70% | -60.67% |
| EBIT | -6.41% | -38.22% | -65.84% | -99.84% | -67.47% |
| EBITDA | -6.43% | -38.28% | -65.93% | -100.07% | -67.67% |
| EPS Basic | 7.85% | -18.80% | -37.69% | -48.61% | -16.99% |
| Normalized Basic EPS | 7.85% | -18.80% | -37.69% | -48.61% | -16.99% |
| EPS Diluted | 7.85% | -18.80% | -37.69% | -48.61% | -16.99% |
| Normalized Diluted EPS | 7.85% | -18.80% | -37.69% | -48.61% | -16.99% |
| Average Basic Shares Outstanding | 21.26% | 20.48% | 23.26% | 26.41% | 35.10% |
| Average Diluted Shares Outstanding | 21.26% | 20.48% | 23.26% | 26.41% | 35.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |